Intraoperative Near Infrared Molecular Imaging of Lung Cancer

项目概要/摘要 非小细胞肺癌（NSCLC）是一种预后差的毁灭性疾病。当患者 首次诊断为NSCLC，该人通常会接受诊断性支气管镜检查和/或 治疗性手术这两种方法存在限制其成功的技术挑战，例如 活检不准确，未能定位结节和淋巴结，遗漏隐匿性肿瘤，以及阳性 利润率因此，这些手术的失败率为40%。This Project will use 在近红外（NIR）范围内的光学成像，以产生这些问题的实际解决方案， 使这两种常见的程序更安全，更有效，并改善结果。的目标 本项目是为了测试假设，术中成像在近红外光谱与目标 分子示踪剂可以识别肿瘤细胞，以改善用于肿瘤细胞的程序。 NSCLC患者的管理。本计划项目的创新将体现在以下矩阵中： 鸡尾酒染料开发，新的近红外相机设备和临床翻译。有三个具体的 这个项目的目标。第一，研制一套靶向近红外分子成像造影剂 对NSCLC的一系列不同靶点具有敏感性和特异性。第二，发展和融合 高NIR光谱敏感成像平台到常用的白色光成像设备中， 可以在临床过程中使用。第三，应用这些创新来解决常见的临床问题， 问题，以影响病人的护理。如果成功的话，分子光学成像解决方案 在这项建议中，将立即适用于数十万肺癌患者， 每年.

Project Summary/Abstract Non-small cell lung cancer (NSCLC) is a devastating disease with a poor outcome. When a patient is first diagnosed with NSCLC, the person would typically undergo diagnostic bronchoscopy and/or therapeutic surgery. These two procedures have technical challenges that limit their success such as inaccurate biopsies, failure to locate nodules and lymph nodes, missed occult tumors, and positive margins. As a consequence, there is a 40% failure rate for these procedures. This Project will use optical imaging in the near-infrared (NIR) range to generate practical solutions to these problems and make these two common procedures safer, more efficient, and have improved outcomes. The goal of this Project is to test the hypothesis that intraoperative imaging in the NIR spectrum with targeted molecular tracers can identify tumor cells in order to improve procedures that are utilized for the management of patients with NSCLC. The innovation of this Program Project will be in the matrix of cocktail dye development, new NIR camera devices, and clinical translation. There are three specific goals of this Project. First, to develop a set of targeted near-infrared molecular imaging contrast agents that are sensitive and specific to a range of distinct targets on NSCLC. Second, to develop and integrate highly NIR spectral sensitive imaging platforms into commonly used white light imaging devices so they can be utilized during clinical procedures. And third, to apply these innovations to solve common clinical problems in order to impact patient care. If successful, the molecular optical imaging solution presented in this proposal would be immediately applicable to several hundred thousand lung cancer patients each year.